Paper22242561
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
Czock D and 2 others. Br J Clin Pharmacol, 2012. Cited by 20 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Papers, record 22242561. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22242561
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Kidney | Major topic |
| Peptides | Major topic |
| Pharmaceutical Preparations | Major topic |
| Proteins | Major topic |
| Renal Insufficiency | Major topic |
| Dose-Response Relationship, Drug | |
| Half-Life | |
| Humans | |
| Metabolic Clearance Rate | |
| Models, Theoretical | |
| Molecular Weight |
Source PubMed
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16,554,449 | The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. | J Clin Pharmacol | 2006 | https://conductscience.org/library/papers/16554449 | PubMed |
| 2 | 9,098,666 | Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. | Drugs | 1997 | https://conductscience.org/library/papers/9098666 | PubMed |
| 3 | 8,222,296 | Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. | Clin Endocrinol (Oxf) | 1993 | https://conductscience.org/library/papers/8222296 | PubMed |
| 4 | 9,354,307 | Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. | Br J Clin Pharmacol | 1997 | https://conductscience.org/library/papers/9354307 | PubMed |
| 5 | 15,373,927 | Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. | Br J Clin Pharmacol | 2004 | https://conductscience.org/library/papers/15373927 | PubMed |
| 6 | 8,967,884 | The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure. | Artif Organs | 1995 | https://conductscience.org/library/papers/8967884 | PubMed |
| 7 | 16,259,772 | The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. | J Pharm Pharmacol | 2005 | https://conductscience.org/library/papers/16259772 | PubMed |
| 8 | 18,807,251 | Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. | Eur J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/18807251 | PubMed |
| 9 | 12,678,690 | Drug metabolism in chronic renal failure. | Curr Drug Metab | 2003 | https://conductscience.org/library/papers/12678690 | PubMed |
| 10 | 10,541,299 | Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. | J Am Soc Nephrol | 1999 | https://conductscience.org/library/papers/10541299 | PubMed |
| 11 | 12,844,139 | Pharmacokinetics of anakinra in subjects with different levels of renal function. | Clin Pharmacol Ther | 2003 | https://conductscience.org/library/papers/12844139 | PubMed |
| 12 | 17,425,627 | Effect of renal impairment on the pharmacokinetics of exenatide. | Br J Clin Pharmacol | 2007 | https://conductscience.org/library/papers/17425627 | PubMed |
| 13 | 1,101,090 | Insulin and the kidney. | Nephron | 1975 | https://conductscience.org/library/papers/1101090 | PubMed |
| 14 | 9,848,789 | Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. | J Am Soc Nephrol | 1998 | https://conductscience.org/library/papers/9848789 | PubMed |
| 15 | 12,753,429 | Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. | Pharmacol Toxicol | 2003 | https://conductscience.org/library/papers/12753429 | PubMed |
| 16 | 16,945,116 | Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration. | Br J Clin Pharmacol | 2007 | https://conductscience.org/library/papers/16945116 | PubMed |
| 17 | 17,555,463 | Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency. | Br J Clin Pharmacol | 2007 | https://conductscience.org/library/papers/17555463 | PubMed |
| 18 | 20,384,392 | CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. | Clin Pharmacokinet | 2010 | https://conductscience.org/library/papers/20384392 | PubMed |
| 19 | 9,336,364 | IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9336364 | PubMed |
| 20 | 19,702,530 | Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. | Curr Drug Metab | 2009 | https://conductscience.org/library/papers/19702530 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,656,976 | Beyond complement: comprehensive assessment of factor XIII plasma dynamics and genetics in atypical hemolytic uremic syndrome. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42656976 | PubMed |
| 42,524,171 | Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering. | Biophysica | 2026 | https://conductscience.org/library/papers/42524171 | PubMed |
| 41,892,463 | Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892463 | PubMed |
| 40,519,647 | A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations. | J Pharm Policy Pract | 2025 | https://conductscience.org/library/papers/40519647 | PubMed |
| 37,231,199 | Impact of Organ Impairment on the Pharmacokinetics of Therapeutic Peptides and Proteins. | AAPS J | 2023 | https://conductscience.org/library/papers/37231199 | PubMed |
| 36,588,717 | Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36588717 | PubMed |
| 35,076,485 | Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted? | Antibodies (Basel) | 2021 | https://conductscience.org/library/papers/35076485 | PubMed |
| 34,698,086 | Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs). | Antibodies (Basel) | 2021 | https://conductscience.org/library/papers/34698086 | PubMed |
| 34,213,592 | The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer. | Cancer Chemother Pharmacol | 2021 | https://conductscience.org/library/papers/34213592 | PubMed |
| 31,544,862 | Factors Affecting the Pharmacology of Antibody-Drug Conjugates. | Antibodies (Basel) | 2018 | https://conductscience.org/library/papers/31544862 | PubMed |
| 31,544,809 | Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients. | Antibodies (Basel) | 2019 | https://conductscience.org/library/papers/31544809 | PubMed |
| 25,366,889 | Strategic approaches to optimizing peptide ADME properties. | AAPS J | 2015 | https://conductscience.org/library/papers/25366889 | PubMed |
| 23,187,965 | Pharmacokinetics of teduglutide in subjects with renal impairment. | Eur J Clin Pharmacol | 2013 | https://conductscience.org/library/papers/23187965 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22242561
GET https://conductscience.org/api/papers/v1/22242561/references?page=2